The Search Within Fluids
In a pioneering initiative that blends science with compassion, scientists in Manchester are turning to a humble, life‑giving substance—breast milk—to potentially spot breast cancer far earlier than current methods allow. A study led by the University of Manchester suggests that tiny fragments of genetic material shed by cancerous cells may accumulate in the fluid, offering a non‑invasive glimpse into breast tissue health. If successful, this breakthrough could revolutionise how doctors screen women who are pregnant or having recently given birth, bringing critical diagnosis opportunities closer to patients before symptoms appear.
Personal Motivation Fuels the Research
Behind every drop collected lies the courage of volunteers willing to contribute to medical progress. One of the first mothers to donate was Hannah Brennan, 31, from Glossop in Derbyshire. She holds a six‑month‑old girl named Ada alongside younger siblings, yet her drive stems from a personal loss—a grandmother who passed away at fifty‑one from breast cancer. “I’m doing this for her,” she explained, her voice steady despite the responsibility of collecting multiple samples. As a registered midwifery student completing a PhD at the university, Hannah sees the work as a way to give back. “I want other mothers to benefit from my involvement,” she said. Her participation exemplifies the spirit of citizen science, where everyday individuals become partners in advancing diagnostic possibilities.
The Science of Spotting Tumours in Milk
The biological basis for this experiment rests on the discovery of circulating tumour DNA within breast milk. Researchers have isolated minute fragments of genetic material that originate from malignant cells and travel through the bloodstream to the mammary gland. These fragments, once released into the milk ducts, persist in the fluid—a phenomenon now being mapped and analysed at the National Biomarker Centre at the Christie NHS Foundation Trust. “We know surprisingly little about the genetic changes to breast milk,” notes Dr Niki Flaum, the study’s lead investigator and a consultant oncologist at the trust. “This bio‑fluid has been remarkably under‑researched until now.”
Building a Biobank for Future Screening
The ambition extends beyond a single study. Over the coming months, the project aims to recruit forty women—twenty‑five with average risk and fifteen from high‑risk categories, including those carrying BRCA gene mutations. The ultimate goal is to construct the Manchester Breast Biofluid Biobank, a repository of over two hundred samples that will serve researchers worldwide. “The aim is to create a resource that can inform screening protocols for both the general public and women with elevated familial or genetic risks,” explains Dr Florent Mouliere, who leads the laboratory team responsible for analysing the fluid. The Christie Charity has pledged significant backing, promising £30 million in funding by 2030 to propel these efforts forward.
A Mother’s Journey Toward Participation
For Hannah Brennan, the experience has been straightforward yet meaningful. After receiving a call from the recruitment team, she set aside time to complete a blood draw, offer a portion of her breast milk, and fill out a brief questionnaire. “Participating felt simple enough,” she reflected. “But knowing that each sample contributes to something larger gives it purpose.” Her motivation is deeply personal, rooted in memory and hope. “When I think of my grandmother, whose life was cut short by this disease, I want my work to extend that legacy,” she shared. The act of giving becomes a quiet tribute, a way to turn personal grief into collective progress.
Why it Matters
The stakes are high because breast cancer remains the leading cause of cancer‑related mortality among British women aged thirty‑five to sixty‑four, and the timing of diagnosis profoundly influences outcomes. For those navigating pregnancy, early detection is especially crucial since imaging techniques used during lactation are frequently unreliable, often missing subtle signs until the disease has already progressed. If the Manchester team can demonstrate that breast milk retains tumour DNA—a marker that proves invisible to standard scans—it could open a pathway to intervention far sooner, improving survival rates and reducing the emotional burden on families facing a late‑stage diagnosis. More broadly, this approach promises to reshape preventive strategies, allowing high‑risk women to monitor their health without stopping breastfeeding, thereby preserving the benefits of milk while safeguarding their wellbeing.
